SRC and non-small cell lung carcinoma: Finally, EGFR inhibitors, Gefitinib and Erlotinib, and Src inhibitor, Dasatinib, are all shown to reduce the levels of SOX2 by blocking the EGFR/SRC/AKT signaling, eventually suppressing the self-renewal properties of cancer stem cells in non-small cell lung cancer (Singh et al., 2012).